Skip to content
Search

Latest Stories

Deadline for mandatory Covid-19 jab nears for frontline staff, thousands face termination

As the deadline for the frontline healthcare workers to get fully vaccinated approaches, tens of thousands of NHS staff who have not yet taken the Covid-19 vaccine face termination in just a fortnight.

Although it is estimated that the majority of NHS staff have been fully jabbed, health and social care providers in England will soon be needed to ensure that all those working in areas regulated by the Care Quality Commission (CQC), are fully vaccinated against Covid-19 before the April 1, 2022.


Those who are exempted from taking the vaccination do not fall under this purview.

According to the NHS England guidance around Vaccination as a Condition of Deployment (VCOD) for healthcare workers, all frontline staff must have had both the doses by April 1, meaning that by February 3 the first must have been administered and the second by March 31.

All unvaccinated frontline workers will be called into formal meetings from February 4 and given a warning of dismissal. Notices will then be issued from that day, with March 31 marking the end of the notice period

More than 80,000 staff, accounting for nearly 6 per cent of the NHS's entire workforce, remain unvaccinated, Daily Mail reported.

The guidance, released on January 14, advised managers to move unvaccinated staff from the frontline into roles which do not involve direct patient contact.

Moreover, employers don’t have to help staff find “suitable alternative employment” and redundancy payments will not be made to those who are dismissed.

The guidance states: “It is important to note this is not a redundancy exercise.”

“In the context of the regulations, there is no diminishment or cessation of work of a particular kind.

“Employers will not be concerned with finding “suitable alternative employment” and there will be no redundancy entitlements, including payments, whether statutory or contractual, triggered by this process.”

Meanwhile, unions have warned that if the 'no jab, no job' policy goes ahead in April it would have a 'catastrophic impact' on the health service.

Reacting to the latest guidance, the Pharmacists' Defence Association stated that “encouraging and informing the NHS workforce is still the best way to increase vaccination uptake.”

The association also supported calls from the Trade Union Congress (TUC) for the government to delay the implementation of this policy.

PDA stated: “At a time when the NHS is facing considerable workforce issues because of staff absences due to Covid-19, there is a significant risk around patient safety and the ability for essential services to be maintained should non-vaccinated staff be removed from frontline roles.”

Meanwhile, the association continues to encourage its members to participate in the vaccination programme.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less